C12N 2310/113
Targeting other non-coding nucleic acids
Official title: targeting other non-coding nucleic acids, e.g. antagomirs
C12N2310/113 (Targeting other non-coding nucleic acids) appears on 859 US grants and 1,545 published applications in this corpus.
Search patents in C12N- Granted patents
- 859
- Published applications
- 1,545
- Assignees
- 540
- Inventors
- 2,226
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 5 |
| 2006 | 0 | 3 |
| 2007 | 1 | 26 |
| 2008 | 0 | 5 |
| 2009 | 2 | 21 |
| 2010 | 10 | 33 |
| 2011 | 4 | 40 |
| 2012 | 23 | 108 |
| 2013 | 32 | 80 |
| 2014 | 62 | 95 |
| 2015 | 90 | 122 |
| 2016 | 93 | 148 |
| 2017 | 92 | 100 |
| 2018 | 83 | 106 |
| 2019 | 79 | 80 |
| 2020 | 53 | 98 |
| 2021 | 52 | 82 |
| 2022 | 61 | 95 |
| 2023 | 40 | 97 |
| 2024 | 35 | 88 |
| 2025 | 28 | 74 |
| 2026 | 18 | 39 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Pharmaceutical composition containing HERES expression inhibitor for preventing or treating squamous cell carcinoma25 Aug 2026US 12,716,066 B2Industry-Academic Cooperation Foundation, Yonsei University
- Regulation of von Willebrand factor (VWF)18 Aug 2026US 12,709,754 B2Band Therapeutics, LLC
- RNA G-quadruplex structure in pre-miRNA-1229 as a therapeutic target for Alzheimer's disease and various cancers11 Aug 2026US 12,703,863 B2Duquesne University of the Holy Spirit
- Thrombus imaging aptamers and methods of using same4 Aug 2026US 12,697,401 B2Duke University
- Inhibitor of miR-129 and uses thereof30 Jun 2026US 12,668,795 B2Fondazione Irccs “Ca' Granda—Ospedale Maggiore” Policlinico Di Milano
- Optimized gapmers antisense oligonucleotides for increasing foxg1 expression8 Oct 2026US 2026/0308582 A1EliGab Tx LLC
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- 3'-utr sequences for stabilization of rna1 Oct 2026US 2026/0297594 A1BioNTech SE
- Compositions and methods to modulate idiopathic pulmonary fibrotic associated long noncoding rnas24 Sep 2026US 2026/0286360 A1HAYA Therapeutics SA
- Methods and compositions targeting LINC01929 to increase antigen presentation17 Sep 2026US 2026/0275335 A1Oncolinc Therapeutics Inc
Most cited
By later US patents
- Oligomeric compounds and compositions for use in modulation of small non-coding RNAs132US 7,683,036 B2Regulus Therapeutics Inc. · 2010
- Chemically modified oligonucleotides123US 7,582,744 B2Alnylam Pharmaceuticals, Inc. · 2009
- Conjugated antisense compounds and their use122US 9,127,276 B2Isis Pharmaceuticals, Inc. · 2015
- Compound and method for treating myotonic dystrophy84US 8,835,402 B2Sarepta Therapeutics, Inc. · 2014
- Oligomeric compounds and compositions for use in modulation of small non-coding RNAS57US 8,110,558 B2Regulus Therapeutics Inc. · 2012